A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol

Long-acting injectable antiretroviral (LA-ARV) drugs with low toxicity profiles and propensity for drug-drug interactions are a goal for future ARV regimens. C34-PEG(4)-Chol is a novel cholesterol tagged LA HIV-fusion-inhibitor (FI). We assessed pre-clinical toxicology and first-in-human administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, Killian, Traboni, Cinzia, Penchala, Sujan Dily, Bouliotis, Georgios, Doyle, Nicki, Libri, Vincenzo, Khoo, Saye, Ashby, Deborah, Weber, Jonathan, Nicosia, Alfredo, Cortese, Riccardo, Pessi, Antonello, Winston, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572697/
https://www.ncbi.nlm.nih.gov/pubmed/28842581
http://dx.doi.org/10.1038/s41598-017-09230-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572697/
https://www.ncbi.nlm.nih.gov/pubmed/28842581
http://dx.doi.org/10.1038/s41598-017-09230-0

Ejemplares similares